Pharmaxis files Aridol in Korea

Australia's Pharmaxis has taken its first step into the Asian market, with the filing for Korean marketing approval of its lung function test Aridol. Aridol was recently cleared in 13 European countries, and is already being sold in Sweden and Australia.

Korea is the first Asian country that Pharmaxis has filed a New Drug Application, and was chosen because of the high patient numbers and acceptance of bronchial provocation tests in diagnosing and managing respiratory disease.

"Korea has an estimated 2.5 million asthma sufferers and another 185,000 new asthma cases are being diagnosed every year," said Pharmaxis chief executive Alan Robertson.